Balyasny Asset Management
SWTX

Balyasny Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Balyasny Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,000
Closed -$1.43M – 3222
2022
Q3 		$1.43M Buy
+50,000
New +$1.43M ﹤0.01% 1661

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's SWTX Position: Q3 2025 in Review

Balyasny Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 705,364 shares — an estimated $33.1M sold.

Balyasny Asset Management first reported a position in SWTX in Q1 2021 and held it in 5 quarters. The position peaked at $33.1M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Balyasny Asset Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 705,364 SpringWorks Therapeutics shares in Q3 2025, an estimated $33.1M.
  • Balyasny Asset Management first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 5 quarters.
  • Balyasny Asset Management's SpringWorks Therapeutics position peaked at $33.1M in Q2 2025.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.